Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET

Company Participants

Matt Roache - Director, Investor Relations

Tom McCourt - Chief Executive Officer

Mike Shetzline - Chief Medical Officer

Sravan Emany - Chief Financial Officer

Conference Call Participants

Hannah Monigatti - JPMorgan

David Amsellem - Piper Sandler

Tim Chiang - Northland Capital Markets

Boris Peaker - Cowen and Company

Operator

Good morning. My name is Joseph and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals First Quarter 2022 Investor Update Call. [Operator Instructions] Thank you. Matt Roache, Director of Investor Relations, you may begin your conference.

Matt Roache

Thank you, Joseph. Good morning and thanks for joining us for our first quarter 2022 investor update. Our press release issued this morning can be found on our website. Today’s call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. Discussion of these statements and risk factors is available on the current Safe Harbor statement slide and will be under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2021 and in our future SEC filings.

All forward-looking statements speak as of the date of this presentation and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to and not a substitute for or superior to GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures.

During today’s call, Tom McCourt, our CEO, will review our strategic priorities, provide an update on the commercial performance of LINZESS; Mike Shetzline, our Chief Medical Officer, will discuss our pipeline; and Sravan Emany, our Chief Financial Officer, will review our financial results and guidance.

Today’s webcast includes slides. For those of you dialing in, please go to the Events section of our website to access the accompanying slides separately.

With that, I will turn the call over to Tom.

Tom McCourt

Thanks, Matt. Good morning, everyone and thanks for joining us today. I am delighted to announce our Q1 results this morning. Maintaining last year’s momentum we are off to a tremendous start this year as demonstrated by the continued strong business performance, initiation of IW-3300 and CNP-104 clinical studies and another quarter of delivering profitability and positive cash flow from operations.